Telix Pharmaceuticals Stock Working Capital
TLX Stock | 25.74 0.80 3.21% |
Telix Pharmaceuticals fundamentals help investors to digest information that contributes to Telix Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Telix Stock. The fundamental analysis module provides a way to measure Telix Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Telix Pharmaceuticals stock.
Net Working Capital is likely to drop to about 56.9 M in 2024. Change In Working Capital is likely to gain to about (54.7 M) in 2024. Telix | Working Capital |
Telix Pharmaceuticals Company Working Capital Analysis
Telix Pharmaceuticals' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Telix Pharmaceuticals Working Capital | 67.44 M |
Most of Telix Pharmaceuticals' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Telix Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Competition |
Telix Net Invested Capital
Net Invested Capital |
|
Based on the company's disclosures, Telix Pharmaceuticals has a Working Capital of 67.44 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The working capital for all Australia stocks is notably lower than that of the firm.
Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
All Next | Launch Module |
Telix Fundamentals
Return On Equity | 0.2 | ||||
Return On Asset | 0.0797 | ||||
Profit Margin | 0.08 % | ||||
Operating Margin | 0.09 % | ||||
Current Valuation | 8.52 B | ||||
Shares Outstanding | 334.72 M | ||||
Shares Owned By Insiders | 41.42 % | ||||
Shares Owned By Institutions | 17.88 % | ||||
Price To Book | 21.33 X | ||||
Price To Sales | 13.01 X | ||||
Revenue | 496.66 M | ||||
Gross Profit | 98.54 M | ||||
EBITDA | 22.97 M | ||||
Net Income | 5.21 M | ||||
Total Debt | 17.45 M | ||||
Book Value Per Share | 1.21 X | ||||
Cash Flow From Operations | 23.88 M | ||||
Earnings Per Share | 0.15 X | ||||
Target Price | 25.62 | ||||
Beta | 2.38 | ||||
Market Capitalization | 8.4 B | ||||
Total Asset | 398.3 M | ||||
Retained Earnings | (263.67 M) | ||||
Working Capital | 67.44 M | ||||
Net Asset | 398.3 M |
About Telix Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telix Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telix Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telix Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.